Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag

Thomas K. Karikari, Alexandra Turner, Robert Stass, Leonie C.Y. Lee, Bethany Wilson, David A. Nagel, Eric J. Hill, Kevin G. Moffat

Research output: Contribution to journalArticle

Abstract

Recombinant tau protein is widely used to study the biochemical, cellular and pathological aspects of tauopathies, including Alzheimer's disease and frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTPD-17). Pure tau in high yield is a requirement for in vitro evaluation of the protein's physiological and toxic functions. However, the preparation of recombinant tau is complicated by the protein's propensity to aggregate and form truncation products, necessitating the use of multiple, time-consuming purification methods. In this study, we investigated parameters that influence the expression of wild type and FTPD-17 pathogenic tau, in an attempt to identify ways to maximise expression yield. Here, we report on the influence of the choice of host strain, induction temperature, duration of induction, and media supplementation with glucose on tau expression in Escherichia coli. We also describe a straightforward process to purify the expressed tau proteins using immobilised metal affinity chromatography, with favourable yields over previous reports. An advantage of the described method is that it enables high yield production of functional oligomeric and monomeric tau, both of which can be used to study the biochemical, physiological and toxic properties of the protein.

LanguageEnglish
Pages44-54
Number of pages11
JournalProtein Expression and Purification
Volume130
Early online date20 Sep 2016
DOIs
Publication statusPublished - Feb 2017

Fingerprint

tau Proteins
Frontotemporal Dementia
Histidine
Poisons
Alzheimer Disease
Tauopathies
Chromosomes, Human, Pair 17
Proteins
Affinity Chromatography
Recombinant Proteins
Metals
Escherichia coli
Glucose
Temperature

Bibliographical note

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Funding: National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)’s CRACKIT: Untangle (NC/C013101/1); University of Warwick Chancellor's Scholarship; and BBSRC (BB/J014532/1).

Supplementarydatarelatedtothisarticlecanbefoundathttp://dx.doi.org/10.1016/j.pep.2016.09.009.

Keywords

  • Alzheimer's disease
  • expression
  • FTPD-17
  • microtubule-associated protein tau
  • purification
  • tau
  • tauopathies

Cite this

Karikari, Thomas K. ; Turner, Alexandra ; Stass, Robert ; Lee, Leonie C.Y. ; Wilson, Bethany ; Nagel, David A. ; Hill, Eric J. ; Moffat, Kevin G. / Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. In: Protein Expression and Purification. 2017 ; Vol. 130. pp. 44-54.
@article{6aad43892a034a0fa54ffa8aca6321dd,
title = "Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag",
abstract = "Recombinant tau protein is widely used to study the biochemical, cellular and pathological aspects of tauopathies, including Alzheimer's disease and frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTPD-17). Pure tau in high yield is a requirement for in vitro evaluation of the protein's physiological and toxic functions. However, the preparation of recombinant tau is complicated by the protein's propensity to aggregate and form truncation products, necessitating the use of multiple, time-consuming purification methods. In this study, we investigated parameters that influence the expression of wild type and FTPD-17 pathogenic tau, in an attempt to identify ways to maximise expression yield. Here, we report on the influence of the choice of host strain, induction temperature, duration of induction, and media supplementation with glucose on tau expression in Escherichia coli. We also describe a straightforward process to purify the expressed tau proteins using immobilised metal affinity chromatography, with favourable yields over previous reports. An advantage of the described method is that it enables high yield production of functional oligomeric and monomeric tau, both of which can be used to study the biochemical, physiological and toxic properties of the protein.",
keywords = "Alzheimer's disease, expression, FTPD-17, microtubule-associated protein tau, purification, tau, tauopathies",
author = "Karikari, {Thomas K.} and Alexandra Turner and Robert Stass and Lee, {Leonie C.Y.} and Bethany Wilson and Nagel, {David A.} and Hill, {Eric J.} and Moffat, {Kevin G.}",
note = "{\circledC} 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Funding: National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)’s CRACKIT: Untangle (NC/C013101/1); University of Warwick Chancellor's Scholarship; and BBSRC (BB/J014532/1). Supplementarydatarelatedtothisarticlecanbefoundathttp://dx.doi.org/10.1016/j.pep.2016.09.009.",
year = "2017",
month = "2",
doi = "10.1016/j.pep.2016.09.009",
language = "English",
volume = "130",
pages = "44--54",
journal = "Protein Expression and Purification",
issn = "1046-5928",
publisher = "Academic Press Inc.",

}

Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. / Karikari, Thomas K.; Turner, Alexandra; Stass, Robert; Lee, Leonie C.Y.; Wilson, Bethany; Nagel, David A.; Hill, Eric J.; Moffat, Kevin G.

In: Protein Expression and Purification, Vol. 130, 02.2017, p. 44-54.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag

AU - Karikari, Thomas K.

AU - Turner, Alexandra

AU - Stass, Robert

AU - Lee, Leonie C.Y.

AU - Wilson, Bethany

AU - Nagel, David A.

AU - Hill, Eric J.

AU - Moffat, Kevin G.

N1 - © 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). Funding: National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)’s CRACKIT: Untangle (NC/C013101/1); University of Warwick Chancellor's Scholarship; and BBSRC (BB/J014532/1). Supplementarydatarelatedtothisarticlecanbefoundathttp://dx.doi.org/10.1016/j.pep.2016.09.009.

PY - 2017/2

Y1 - 2017/2

N2 - Recombinant tau protein is widely used to study the biochemical, cellular and pathological aspects of tauopathies, including Alzheimer's disease and frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTPD-17). Pure tau in high yield is a requirement for in vitro evaluation of the protein's physiological and toxic functions. However, the preparation of recombinant tau is complicated by the protein's propensity to aggregate and form truncation products, necessitating the use of multiple, time-consuming purification methods. In this study, we investigated parameters that influence the expression of wild type and FTPD-17 pathogenic tau, in an attempt to identify ways to maximise expression yield. Here, we report on the influence of the choice of host strain, induction temperature, duration of induction, and media supplementation with glucose on tau expression in Escherichia coli. We also describe a straightforward process to purify the expressed tau proteins using immobilised metal affinity chromatography, with favourable yields over previous reports. An advantage of the described method is that it enables high yield production of functional oligomeric and monomeric tau, both of which can be used to study the biochemical, physiological and toxic properties of the protein.

AB - Recombinant tau protein is widely used to study the biochemical, cellular and pathological aspects of tauopathies, including Alzheimer's disease and frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTPD-17). Pure tau in high yield is a requirement for in vitro evaluation of the protein's physiological and toxic functions. However, the preparation of recombinant tau is complicated by the protein's propensity to aggregate and form truncation products, necessitating the use of multiple, time-consuming purification methods. In this study, we investigated parameters that influence the expression of wild type and FTPD-17 pathogenic tau, in an attempt to identify ways to maximise expression yield. Here, we report on the influence of the choice of host strain, induction temperature, duration of induction, and media supplementation with glucose on tau expression in Escherichia coli. We also describe a straightforward process to purify the expressed tau proteins using immobilised metal affinity chromatography, with favourable yields over previous reports. An advantage of the described method is that it enables high yield production of functional oligomeric and monomeric tau, both of which can be used to study the biochemical, physiological and toxic properties of the protein.

KW - Alzheimer's disease

KW - expression

KW - FTPD-17

KW - microtubule-associated protein tau

KW - purification

KW - tau

KW - tauopathies

UR - http://www.scopus.com/inward/record.url?scp=84991480436&partnerID=8YFLogxK

U2 - 10.1016/j.pep.2016.09.009

DO - 10.1016/j.pep.2016.09.009

M3 - Article

VL - 130

SP - 44

EP - 54

JO - Protein Expression and Purification

T2 - Protein Expression and Purification

JF - Protein Expression and Purification

SN - 1046-5928

ER -